Cost-effectiveness analysis of vaccination strategies against meningococcal disease for children under nine years of age in China

References

• Rouphael NG, Stephens DS. Neisseria meningitidis: biology, microbiology, and epidemiology. Methods Mol Biol. 2012;799:1–11.
   PubMedGoogle Scholar
• Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM. Meningococcal disease. N Engl J Med. 2001;344(18):1378–88. doi:10.1056/NEJM200105033441807.
   PubMed Web of Science ®Google Scholar
• Peterson ME, Li Y, Shanks H, Mile R, Nair H, Kyaw MH. Serogroup-specific meningococcal carriage by age group: a systematic review and meta-analysis. BMJ Open. 2019;9(4):e024343. doi:10.1136/bmjopen-2018-024343.
   PubMed Web of Science ®Google Scholar
• Pace D, Pollard AJ. Meningococcal disease: clinical presentation and sequelae. Vaccine. 2012;30:B3–B9. doi:10.1016/j.vaccine.2011.12.062.
   PubMed Web of Science ®Google Scholar
• Xu Y, Li Y, Wang S, Li M, Xu M, Ye Q. Meningococcal vaccines in China. Hum Vaccin Immunother. 2021;17(7):2197–204. doi:10.1080/21645515.2020.1857201.
   PubMed Web of Science ®Google Scholar
• Li J, Shao Z, Liu G, Bai X, Borrow R, Chen M, Guo Q, Han Y, Li Y, Taha M-K, et al. Meningococcal disease and control in China: findings and updates from the global meningococcal initiative (GMI). J Infect. 2018;76(5):429–37. doi:10.1016/j.jinf.2018.01.007.
   PubMed Web of Science ®Google Scholar
• Xu J, Chen Y, Yue M, Yu J, Han F, Xu L, Shao Z. Prevalence of Neisseria meningitidis serogroups in invasive meningococcal disease in China, 2010–2020: a systematic review and meta-analysis. Hum Vaccin Immunother. 2022;18(5):2071077. doi:10.1080/21645515.2022.2071077.
   PubMed Web of Science ®Google Scholar
• Xie Z, Huang H, Zhang W, Gou J, Huang L, Wang X. Safety of a domestic group A, C, Y, and W135 meningococcal conjugate vaccine among 3-month-old, 6–23-month-old, and 2–6-year-old children: a phase III clinical trial. Chin J Vaccines Immun. 2021;27(6):648–54.
   Google Scholar
• Pichichero M, Casey J, Blatter M, Rothstein E, Ryall R, Bybel M, Gilmet G., Papa T. Comparative trial of the safety and immunogenicity of quadrivalent (A, C, Y, W-135) meningococcal polysaccharide-diphtheria conjugate vaccine versus quadrivalent polysaccharide vaccine in two-to ten-year-old children. Pediatr Infect Dis J. 2005;24(1):57–62. doi:10.1097/01.inf.0000148928.10057.86.
   PubMed Web of Science ®Google Scholar
• Oliveira LHD, Jauregui B, Carvalho AF, Giglio N. Impact and effectiveness of meningococcal vaccines: a review. Revista Panamericana de Salud Pública. 2018;41:e158. doi:10.26633/RPSP.2017.158.
   Web of Science ®Google Scholar
• MacDonald NE, Halperin SA, Law BJ, Forrest B, Danzig LE, Granoff DM. Induction of immunologic memory by conjugated vs plain meningococcal C polysaccharide vaccine in toddlers: a randomized controlled trial. JAMA. 1998;280(19):1685–9. doi:10.1001/jama.280.19.1685.
   PubMed Web of Science ®Google Scholar
• Jiang Z. Cost-effectiveness and cost-benefit analysis of meningococcal vaccine immunization in Zhejiang Province from 1978 to 2009. Chin J Vaccines Immun. 2011;17(1):54–8.
   Google Scholar
• Zhang L. Cost-benefit evaluation of meningococcal polysaccharide vaccination in Guizhou province. Chin J Vaccines Immun. 2017;23(4):369–74.
   Google Scholar
• Zhang L, Jiang F, Guan Q, Wang M, Liu M, Rui L, Cost-effectiveness comparison of different immunization strategies for meningococcal polysaccharide vaccine in Guizhou Province. Mod Prev Med. 2021;48(6):1043–5+54.
   Google Scholar
• Zhang HN, Zhang HJ, Lyu Y, Lai X, Feng H, Wang J, Guo J, Fang H. Economic evaluations of immunization strategies for meningococcal vaccines: a systematic review. Chin J New Drugs. 2022;31(13):1331–9.
   Google Scholar
• Li J, Li Y, Shao Z, Li L, Yin Z, Ning G, Xu L, Luo H. Prevalence of meningococcal meningitis in China from 2005 to 2010. Vaccine. 2015;33(8):1092–7. doi:10.1016/j.vaccine.2014.10.072.
   PubMed Web of Science ®Google Scholar
• MacLennan J, Obaro S, Deeks J, Williams D, Pais L, Carlone G, Moxon R, Greenwood B. Immune response to revaccination with meningococcal A and C polysaccharides in Gambian children following repeated immunisation during early childhood. Vaccine. 1999;17(23–24):3086–93. doi:10.1016/S0264-410X(99)00139-5.
   PubMed Web of Science ®Google Scholar
• Reingold A, Hightower A, Bolan G, Jones E, Tiendrebeogo H, Broome C, Ajello G, Adamsbaum C, Phillips C, Yada A. Age-specific differences in duration of clinical protection after vaccination with meningococcal polysaccharide A vaccine. Lancet. 1985;326(8447):114–18. doi:10.1016/S0140-6736(85)90224-7.
   Google Scholar
• MacLennan J, Obaro S, Deeks J, Lake D, Elie C, Carlone G, Moxon ER, Greenwood B. Immunologic memory 5 years after meningococcal A/C conjugate vaccination in infancy. J Infect Dis. 2001;183(1):97–104. doi:10.1086/317667.
   PubMed Web of Science ®Google Scholar
• Cohn AC, MacNeil JR, Harrison LH, Lynfield R, Reingold A, Schaffner W, Zell ER, Plikaytis B, Wang X, Messonnier NE. et al. Effectiveness and duration of protection of one dose of a meningococcal conjugate vaccine. Pediatrics. 2017;139(2). doi: 10.1542/peds.2016-2193.
   PubMed Web of Science ®Google Scholar
• Baxter R, Reisinger K, Block SL, Izu A, Odrljin T, Dull P. Antibody persistence and booster response of a quadrivalent meningococcal conjugate vaccine in adolescents. J Pediatr. 2014;164(6):1409–15. e4. doi:10.1016/j.jpeds.2014.02.025.
   PubMed Web of Science ®Google Scholar
• Gill CJ, Baxter R, Anemona A, Ciavarro G, Dull P. Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo®) or Menactra® among healthy adolescents. Hum Vaccin. 2010;6(11):881–7. doi:10.4161/hv.6.11.12849.
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO guide for standardization of economic evaluations of immunization programmes. 2019.
   Google Scholar
• Horino T, Kato T, Sato F, Sakamoto M, Nakazawa Y, Yoshida M, Onodera S, Kohda M, Matsuo K, Ishiji T. et al. Meningococcemia without meningitis in Japan. Internal Med. 2008;47(17):1543–7. doi:10.2169/internalmedicine.47.1046.
   PubMed Web of Science ®Google Scholar
• Li J, Wu D, Wen N, Zheng H, Shi W, Xu L, Shao ZJ, Yin ZD, Li YX. Serogroup distribution of meningococcal meningitis in China, 2015–2019. Chin J Vaccines Immun. 2020;26(3):241–4.
   Google Scholar
• Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, Rudan I. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10(5):317–28. doi:10.1016/S1473-3099(10)70048-7.
   PubMed Web of Science ®Google Scholar
• Vyse A, Anonychuk A, Jäkel A, Wieffer H, Nadel S. The burden and impact of severe and long-term sequelae of meningococcal disease. Expert Rev Anti Infect Ther. 2013;11(6):597–604. doi:10.1586/eri.13.42.
   PubMed Web of Science ®Google Scholar
• Martinón-Torres F. Deciphering the burden of meningococcal disease: conventional and under-recognized elements. J Adolesc Health. 2016;59(2):S12–S20. doi:10.1016/j.jadohealth.2016.03.041.
   PubMed Web of Science ®Google Scholar
• Wahl B, O’Brien KL, Greenbaum A, Majumder A, Liu L, Chu Y, Lukšić I, Nair H, McAllister DA, Campbell H. et al. Burden of streptococcus pneumoniae and haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000–15. Lancet Global Health. 2018;6(7):744–57. doi:10.1016/S2214-109X(18)30247-X.
   PubMed Web of Science ®Google Scholar
• Yu W, Lu M, Wang H, Rodewald L, Ji S, Ma C, Li Y, Zheng J, Song Y, Wang M. et al. Routine immunization services costs and financing in China, 2015. Vaccine. 2018;36(21):3041–7. doi:10.1016/j.vaccine.2018.04.008.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Monitoring vaccine wastage at country level: guidelines for programme managers. 2005.
   Google Scholar
• Liu W. Investigation on economic burden of three main bacterial meningitis cases in some areas. Beijing: Chinese Center for Disease Control and Prevention; 2016.
   Google Scholar
• Wang A, Xu Z, Ji L. Clinical characteristics and medical costs of diabetics with amputation at central urban hospitals in China. National Med J China. 2012;92(4):224–7.
   Google Scholar
• Yang Y. Evaluation progress of socioeconomic burden of diagnosis and treatment of myopia. Clin J Experiment Ophthalmol. 2019;37(7):582–6.
   Google Scholar
• Tang J, Li Y, Xu L, Chen X, Mao L, Shi W, Lmmunogenicity and persistence of immunity following a booster of group a and group C meningococcal polysaccharide vaccine among children who hadreceived primary vaccination with group a and group C meningococcal polysaccharide conjugate vaccine. Chin J Vaccines Immun. 2020;26(3):245–8.
   Google Scholar
• Bennett JE, Sumner W, Downs SM, Jaffe DM. Parents’ utilities for outcomes of occult bacteremia. Arch Pediatr Adolesc Med. 2000;154:43–8.
   PubMedGoogle Scholar
• Oostenbrink R, Moll HA, Essink-Bot M-L. The EQ-5D and the health utilities index for permanent sequelae after meningitis: a head-to-head comparison. J Clin Epidemiol. 2002;55(8):791–9. doi:10.1016/S0895-4356(02)00448-1.
   PubMed Web of Science ®Google Scholar
• Brown MM, Brown GC, Sharma S, Kistler J, Brown H. Utility values associated with blindness in an adult population. Br J Ophthalmol. 2001;85(3):327–31. doi:10.1136/bjo.85.3.327.
   PubMed Web of Science ®Google Scholar
• Blakeney P, Meyer W, Robert R, Desai M, Wolf S, Herndon D. Long-term psychosocial adaptation of children who survive burns involving 80% or greater total body surface area. J Trauma Acute Care Surg. 1998;44(4):625–34. doi:10.1097/00005373-199804000-00011.
   Google Scholar
• Erickson LJ, De Wals P, McMahon J, Heim S. Complications of meningococcal disease in college students. Clin Infect Dis. 2001;33(5):737–9. doi:10.1086/322587.
   PubMed Web of Science ®Google Scholar
• Jackson LA, Schuchat A, Gorsky RD, Wenger JD. Should college students be vaccinated against meningococcal disease? A cost-benefit analysis. Am J Public Health. 1995;85(6):843–5. doi:10.2105/AJPH.85.6.843.
   PubMed Web of Science ®Google Scholar
• Parent du Châtelet, du Chatelet IP BD, da Silva A, Parent du Châtelet I. Comparison of cost-effectiveness of preventive and reactive mass immunization campaigns against meningococcal meningitis in West Africa: a theoretical modeling analysis. Vaccine. 2001;19(25–26):3420–31. doi:10.1016/S0264-410X(01)00066-4.
   PubMed Web of Science ®Google Scholar
• De Wals P, Coudeville L, Trottier P, Chevat C, Erickson LJ, Nguyen VH. Vaccinating adolescents against meningococcal disease in Canada: a cost-effectiveness analysis. Vaccine. 2007;25(29):5433–40. doi:10.1016/j.vaccine.2007.04.071.
   PubMed Web of Science ®Google Scholar
• De Wals P, Zhou Z. Cost-effectiveness comparison of Monovalent C Versus Quadrivalent ACWY Meningococcal Conjugate Vaccination in Canada. Pediatr Infect Dis J. 2017;36(7):203–7. doi:10.1097/INF.0000000000001512.
   PubMed Web of Science ®Google Scholar
• Delea TE, Weycker D, Atwood M, Neame D, Alvarez FP, Forget E, Langley JM, Chit A. Cost-effectiveness of alternate strategies for childhood immunization against meningococcal disease with monovalent and quadrivalent conjugate vaccines in Canada. PLoS One. 2017;12(5):e0175721. doi:10.1371/journal.pone.0175721.
   PubMed Web of Science ®Google Scholar
• Si S, Zomer E, Fletcher S, Lee J, Liew D. Cost-effectiveness of meningococcal polysaccharide serogroups A, C, W-135 and Y conjugate vaccine in Australian adolescents. Vaccine. 2019;37(35):5009–15. doi:10.1016/j.vaccine.2019.07.008.
   PubMed Web of Science ®Google Scholar
• Watle SV, Næss LM, Tunheim G, Caugant DA, Wisløff T. Cost-effectiveness of meningococcal vaccination of Norwegian teenagers with a quadrivalent ACWY conjugate vaccine. Hum Vaccin Immunother. 2021;17(8):1–11. doi:10.1080/21645515.2021.1880209.
   PubMed Web of Science ®Google Scholar
• Kuznik A, Iliyasu G, Lamorde M, Mahmud M, Musa BM, Nashabaru I, Obaro S, Mohammed I, Habib AG. Cost-effectiveness of expanding childhood routine immunization against Neisseria meningitidis serogroups C, W and Y with a quadrivalent conjugate vaccine in the African meningitis belt. PLoS One. 2017;12(11):e0188595. doi:10.1371/journal.pone.0188595.
   PubMed Web of Science ®Google Scholar
• Sulis G, Horn M, Borrow R, Basta NE. A comparison of national vaccination policies to prevent serogroup B meningococcal disease. Vaccine. 2022;40(26):3647–54. doi:10.1016/j.vaccine.2022.04.101.
   PubMed Web of Science ®Google Scholar
• Beck E, Klint J, Neine M, Garcia S, Meszaros K. Cost-effectiveness of 4CMenB infant vaccination in England: a comprehensive valuation considering the broad impact of serogroup B invasive meningococcal disease. Value Health. 2021;24(1):91–104. doi:10.1016/j.jval.2020.09.004.
   PubMed Web of Science ®Google Scholar